Michelle Ertel1,2, S Allison Staley1,2,3,4, Tam Nguyen1, Austin Johnson1,2, Austin Hopkins1, Nerlyne Desravines1,2, Johnathon Recknagel1,2, Xinyi Zhang1,5, Xianming Tan1,4,5, Leslie H Clark6,7,8,9. 1. University of North Carolina, Chapel Hill, NC, USA. 2. Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA. 3. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA. 4. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 5. Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA. 6. University of North Carolina, Chapel Hill, NC, USA. Leslie_Clark@med.unc.edu. 7. Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA. Leslie_Clark@med.unc.edu. 8. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA. Leslie_Clark@med.unc.edu. 9. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Leslie_Clark@med.unc.edu.
Abstract
BACKGROUND: Minimally invasive surgical (MIS) staging is the standard treatment approach for clinical stage I endometrial cancer. Historical rates of inoperability in endometrial cancer are approximately 10%. Given surgical and medical advancements against increasing population obesity, we aimed to describe a contemporary incidence of medical inoperability in clinical stage I endometrial cancer. PATIENTS AND METHODS: Patients diagnosed with clinical stage I endometrial cancer of any histology from April 2014 to December 2018 were included in this retrospective cohort study. The primary outcome, medical inoperability, was defined as (1) patients deemed inoperable by a gynecologic oncologist at initial consultation, (2) patients deemed inoperable during preoperative clearance, or (3) an aborted hysterectomy. Fisher's exact or χ2, and Student's t-test or Wilcoxon rank sum test were used, as appropriate, for data analysis. Multivariable logistic regression was also employed. RESULTS: Overall, 767 patients were included, of which 4.6% (35/767) were determined to be inoperable. The inoperable group had a higher body mass index (52.7 vs. 33.9, p < 0.001), and increased rates of diabetes (62.8%, 22/35 vs. 27.1%, 199/732, p < 0.001), coronary artery disease (31.4%, 11/35 vs. 7.1%, 52/732, p < 0.001), and hypertension (94.3%, 33/35 vs. 70.2%, 514/732, p < 0.001). Of those with attempted surgical staging, hysterectomy was aborted intraoperatively in 0.68% (5/737). The overall complication rate was 11.6% (86/737). CONCLUSIONS: With maximal surgical effort and MIS, hysterectomy is possible in > 95% of patients with newly diagnosed endometrial cancer treated at a high-volume center. Complication rates were comparable to other trials evaluating the safety of MIS staging for endometrial cancer.
BACKGROUND: Minimally invasive surgical (MIS) staging is the standard treatment approach for clinical stage I endometrial cancer. Historical rates of inoperability in endometrial cancer are approximately 10%. Given surgical and medical advancements against increasing population obesity, we aimed to describe a contemporary incidence of medical inoperability in clinical stage I endometrial cancer. PATIENTS AND METHODS: Patients diagnosed with clinical stage I endometrial cancer of any histology from April 2014 to December 2018 were included in this retrospective cohort study. The primary outcome, medical inoperability, was defined as (1) patients deemed inoperable by a gynecologic oncologist at initial consultation, (2) patients deemed inoperable during preoperative clearance, or (3) an aborted hysterectomy. Fisher's exact or χ2, and Student's t-test or Wilcoxon rank sum test were used, as appropriate, for data analysis. Multivariable logistic regression was also employed. RESULTS: Overall, 767 patients were included, of which 4.6% (35/767) were determined to be inoperable. The inoperable group had a higher body mass index (52.7 vs. 33.9, p < 0.001), and increased rates of diabetes (62.8%, 22/35 vs. 27.1%, 199/732, p < 0.001), coronary artery disease (31.4%, 11/35 vs. 7.1%, 52/732, p < 0.001), and hypertension (94.3%, 33/35 vs. 70.2%, 514/732, p < 0.001). Of those with attempted surgical staging, hysterectomy was aborted intraoperatively in 0.68% (5/737). The overall complication rate was 11.6% (86/737). CONCLUSIONS: With maximal surgical effort and MIS, hysterectomy is possible in > 95% of patients with newly diagnosed endometrial cancer treated at a high-volume center. Complication rates were comparable to other trials evaluating the safety of MIS staging for endometrial cancer.
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: Epidemiology Date: 2007-11 Impact factor: 4.822
Authors: Zachary J Ward; Sara N Bleich; Angie L Cradock; Jessica L Barrett; Catherine M Giles; Chasmine Flax; Michael W Long; Steven L Gortmaker Journal: N Engl J Med Date: 2019-12-19 Impact factor: 91.245
Authors: Sahaja Acharya; Jacqueline Esthappan; Shahed Badiyan; Todd A DeWees; Kari Tanderup; Julie K Schwarz; Perry W Grigsby Journal: Radiother Oncol Date: 2015-12-29 Impact factor: 6.280
Authors: Lauren E Giugale; Nicola Di Santo; Mark E Smolkin; Laura J Havrilesky; Susan C Modesitt Journal: Gynecol Oncol Date: 2012-08-19 Impact factor: 5.482
Authors: Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Devin Coon; Sushil Beriwal; Dwight E Heron; Joseph L Kelley; Robert P Edwards; Paniti Sukumvanich; Kristin K Zorn; Thomas C Krivak Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-06 Impact factor: 7.038